Phase 2 Results Of Investigational Abuse-Deterrent Opioid ALO-01presented By Alpharma
Alpharma Pharmaceuticals LLC, a subsidiary of Alpharma Inc.(NYSE: ALO), a leading global specialty pharmaceutical company, presented results from a Phase 2 study that showed ALO-01, an extended-release morphine sulfate plus sequestered naltrexone, provided similar effectiveness to KADIAN® (morphine sulfate extended-release) Capsules in osteoarthritis patients with moderate-to-severe chronic pain. [click link for full article]
More: continued here
Filed under: Bones on October 20th, 2007